Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
about
DNA vaccine for cancer immunotherapyImmunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanomaPreclinical and clinical development of DNA vaccines for prostate cancer.CSPG4: a prototype oncoantigen for translational immunotherapy studies.Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artAntibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Strategies for cancer vaccine development.Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabLocal and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Immunotherapy for melanoma: current status and perspectives.Harnessing DNA-induced immune responses for improving cancer vaccines.Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults.Trial watch: DNA vaccines for cancer therapy.CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three casesState of the art in tumor antigen and biomarker discovery.Emerging cancer vaccines: the promise of genetic vectors.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma.The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.DNA vaccination: using the patient's immune system to overcome cancerLocal and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Melanoma treatment in review.
P2860
Q28080919-DB66639D-489A-4403-9940-D50B6654B008Q33606137-4ED8D755-90C0-4971-9D1B-8A18E14ED840Q33740811-A4403B1B-BE22-49AD-A19E-68C6FB13CC11Q33862585-6F8F16E4-1EBA-4635-9622-808685A49622Q33907628-3FB889AE-5EFB-4EE7-93B9-25DDBCB6B176Q34000700-4D922D3E-401A-4A65-A1AF-A43E1FE49371Q34038338-B3EB7605-F7B8-4C39-A876-64B6D8383677Q34173622-118406A7-3EA9-4C6F-9114-1D58DDF56B7BQ34522301-AB6DC3F6-7CF0-447A-932B-DA61AEF5FBBDQ34561877-465B26C3-8DBD-42A3-8674-8C103795AB8BQ35289145-68BEE9DE-FE50-4DBA-9B6C-A16B5AC8700CQ35600772-DCAD1AC8-A221-4E2C-8454-3481CA97D160Q36453216-945DF6A9-EF06-47BF-A6C9-CF8B233BB99BQ36694866-CE97D3F7-7B39-465A-ACA7-68E27FCE9083Q36765132-C6E3727D-5200-4FEC-A0D6-07B096F36DE1Q36845824-84F9E8F2-F38C-4651-AC69-BC26525F37B5Q36846646-510C1759-C92E-49F3-A410-36F5E767AC1EQ37132800-4FBE25B1-3F57-4B23-A7E3-A274CA3CF715Q37137464-FDC532E9-77E3-4BD0-ADE6-02DE3F8B0728Q37703163-CC2B1993-3B90-4DFE-A86F-8B5B8300D246Q37727531-3902D413-FE4B-41BC-9FF2-0497D7DEC9E7Q37729321-E4189A5B-4601-4A64-9A01-B13001D7E067Q37825422-9816F237-8D4A-4720-980A-EDECC27AADA0Q41679793-A0B7BB82-FD2E-4EB2-96AE-AAED947B867FQ55217220-1C5773C5-3E8D-449B-830B-E3D328243447
P2860
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and immunogenicity of a ...... rial of patients with melanoma
@ast
Safety and immunogenicity of a ...... rial of patients with melanoma
@en
type
label
Safety and immunogenicity of a ...... rial of patients with melanoma
@ast
Safety and immunogenicity of a ...... rial of patients with melanoma
@en
prefLabel
Safety and immunogenicity of a ...... rial of patients with melanoma
@ast
Safety and immunogenicity of a ...... rial of patients with melanoma
@en
P2093
P2860
P1433
P1476
Safety and immunogenicity of a ...... rial of patients with melanoma
@en
P2093
Alan N Houghton
Francesca Orlandi
Gregor Manukian
Humilidad F Gallardo
Jedd D Wolchok
Jianda Yuan
Katherine Panageas
Lloyd J Old
Paul B Chapman
P2860
P50
P577
2009-06-05T00:00:00Z